Active Recombinant Cynomolgus/Rhesus macaque TIGIT protein, His-tagged

• Cat.No.: TIGIT-121C
• Product Overview: Recombinant Cynomolgus/Rhesus macaque TIGIT protein(Met 89 - Ile 208), fused with His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Cynomolgus/Rhesus macaque
• Tag: His
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4, 10% trehalose.
• Bio-activity: Immobilized Cynomolgus / Rhesus macaque TIGIT, His Tag at 5 μg/mL (100 μL/well) can bind Human CD155, Fc Tag with a linear range of 0.078-2.5 μg/mL.
• Molecular Mass: This protein carries a polyhistidine tag at the C-terminus.The protein has a calculated MW of 15.2 kDa. The protein migrates as 18-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein Length: Met 89 - Ile 208
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >90% as determined by SDS-PAGE. >90% as determined by SEC-HPLC.
• Storage: For long term, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after at:
  -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Reviews

11/25/2022

With its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.

08/05/2017

Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.

05/21/2017

The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.

Q&As

In which types of cancers is TIGIT inhibition being investigated?

TIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.

How is TIGIT relevant in autoimmune diseases?

TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.

What clinical applications does TIGIT have in cancer therapy?

TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.

How does TIGIT differ from other immune checkpoint proteins like PD-1 and CTLA-4?

TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.

Are there any potential side effects associated with TIGIT-targeted therapies?

As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.